S70 Abstracts of the 20 th National Congress of Digestive Diseases / Digestive and Liver Disease 46S (2014) S1–S144 the effect of therapy is immediate 4) the effect of therapy of IFX continue after discontinuing of therapy. P.05.5 COLON CANCER IN IBD PATIENTS TREATED OR UNTREATED WITH ANTI-TNFS: A RETROSPECTIVE MATCHED-PAIR STUDY IN A 13 YEARS FOLLOW UP M. Ascolani * , S. Onali, C. Petruzziello, A. Ruffa, E. Calabrese, F. Zorzi, S. Sedda, G. Condino, F. Pallone, L. Biancone Università Tor Vergata, Roma, Italy Background and aim: Blocking TNFalpha showed efficacy in colitis- associated colon cancer in murine models. In a monocentric retrospective matched-pair study in a cohort of IBD patients (pts) in follow up, we com- pared the frequency of colon cancer in pts treated or untreated with anti-TNFs. The role played by clinical characteristics of IBD in determining the frequency of colon cancer was also evaluated. Material and methods: Clinical records of all IBD pts in follow up from 2000-2013 developing cancer of the lower GI tract (IBD-K) (small intestine, appendix, colon or anal canal) were reviewed. Each IBD-K pt was retro- spectively matched with 2 IBD pts with no cancer (IBD-C), for IBD type (MDC/RCU), gender, age (±5yrs). Anti-TNFs (Infliximab or Adalimumab ≥1 dose) and IMM (≥6mos) use was reported. Statistical analysis: data expressed as median (range); Students’, Chi squared tests. Results: During the study period, 2387 IBD pts were in follow up: 384 (16%) received anti-TNFs. From 2000-2013, 15 IBD pts (9CD,6UC) developed cancer of the lower GI tract 0.62%), including 12 colon cancers (6UC,6CD), 1 ileal adenocarcinoma (1CD), 1 appendix carcinoid (1CD), 1 anal canal squa- mous carcinoma (1CD). Among the 15 IBD-K (7M), median age at diagnosis of cancer was 51 (28-73), IBD duration 19yrs (1-47), CD involved the ileum (I) (n=4), colon (C) n=2), ileum-colon (IC) (n=3); UC was distal (n=3), left (n=1), total (n=2). Among the 15 IBD-K pts,3 (20%) received anti-TNFs and/or IMM (all 3 both). These 3 pts developed cancer (2 colon,1 carcinoid): 2CD (2F, age 40,54yrs, CD duration 28,26 yrs; fistulizing I-C), 1 UC (1F, age30, duration 19yrs; pancolitis). Among the 384/2387 (16%) IBD pts treated with anti-TNFs, colon cancer developed in 3 (0.78%) (IMM in 3). Among the 2003/2387 pts not treated with anti- TNFs, 12 (0.6%) developed cancer of the lower GI tract, 10 (0.5%) colon cancer (p=ns vs anti-TNFs treated). IBD-C included 30 pts (18CD, 12UC; 14 M/16 F, age 54, range 37–75; CD of the I (n=13), C (n=2), I-C (n=3); UC distal (n=11), left (n=1), total (n=0). In the 30 IBD-C, anti-TNFs were used by 6 (20%), being comparable to the 15 IBD-K (3/15; 20%), IMM in 10 (33%) (combined in 2;6.7%). Conclusions: In a retrospective matched-pair study, a comparable low fre- quency of colon cancer was observed in IBD patients treated or untreated with anti-TNFs. P.06.1 RISK FACTORS FOR DEPRESSION AND ANXIETY IN CROHN’S DISEASE C. Bezzio, D. Gridavilla * , F. Furfaro, M. Monteleone, A. Dell’Era, S. Ardizzone, R. De Franchis, G. Maconi Ospedale Luigi Sacco, Milano, Italy Background and aim: Crohn’s disease (CD) is a long-life inflammatory disease affecting gastrointestinal tract, characterised by extraintestinal mani- festations and complications that impaired quality of life. Many patients are affected by psychiatric co-morbidity too, in particular depression and anxiety. A few studies have investigated mood disorders in CD. The aim of our prospective cohort study is to assess prevalence of depression and anxiety and related risk factors in a consecutive series of patients with quiescent CD. Material and methods: Patients aged 18-80 years, with confirmed diagnosis of CD in clinical remission were included. Eligible patients were enrolled during ambulatory visits assessing demo- graphic and clinical features of CD. Within 1 month from the visit patients were interviewed by phone to assess the presence of psychiatric disorders using standardized questionnaires: the Hospital Anxiety and Depression Scale (HADS) and a questionnaire assessing the use of antidepressant or anti-anxiety therapy during the course of CD. Development of anxiety and depression was defined by HADS ≥8 or by the use of antidepressant or anti-anxiety treatment since diagnosis. Statistical analysis were performed by Kruskall–Wallis test, Bonferroni cor- rection, χ 2 test. p-value <0.05 was considered statistically significant. Results: One hundred eighty-five patients were included in the study and 73 patients (39.5%) showed mood disorders since diagnosis. Thirty-four patients (18.4%) have been under psychiatric treatment since diagnosis. Anxiety/depression were significantly correlated with female sex (p: 0.016), history of perianal disease (p: 0.006) and perianal surgery (p: 0.03). Smokers showed a high, although not significant, prevalence of anxiety/depression compared with patients without mood disorders (p: 0.08). Anxiety with or without depression was more significantly correlated with perianal disease and female sex whilst depression alone wasn’t significantly correlated with any variable considered in the study. We didn’t find significant relationship between surgery and anxiety/depression. Conclusions: Among psychiatric disorders, anxiety is the most frequent condition in patient affected by CD in clinical remission. Risk factors for anx- iety/depression were female sex and history of perianal disease and perianal surgery. P.06.2 THE PREVALENCE OF CELIAC DISEASE IS NOT INCREASED IN INFLAMMATORY BOWEL DISEASE (IBD), AND THE PREVALENCE OF IBD IS NOT INCREASED IN PATIENTS WITH CELIAC DISEASE: A 10 YEARS SURVEY L. Cuoco * , R. Castaman, A. D’Alessandro Ospedale San Bortolo, Vicenza, Italy Background and aim: The frequency of association in the same patient of celiac disease (CD) and IBD is uncertain and data are controversial. The aim of this study was to evaluate the prevalence of CD in our IBD patients (pts) and on the other hand the prevalence of IBD in our large CD population. Material and methods: We prospectively evaluated 179 consecutive pts (mean age 38,7 yrs, M 103, F 76) with IBD (71 with Crohn’s disease (CHD), and 108 with ulcerative colitis (UC) diagnosed and followed by our Unit between 2003 and 2013. All pts were tested for IgA anti-transglutaminase (anti-tTG) antibody and total serum IgA. At the time of anti-tTG determina- tion, all pts were free from immunosuppressive therapy for at least 3 months. In 57 CHD pts and in 48 UC pts a duodenal biopsy was also obtained. Then we evaluated for coexisting IBD 774 (422 F, 352 M, mean age 36,8 yrs) consecutive untreated and treated CD pts (avarage follow up 62,4 months): they were subjected to anamnesis, clinical examen, laboratory assessment of flogistic status and, in selected cases, to ultrasonography of small bowel and colonoscopy. Results: Among CHD and UC pts, none showed anti-tTg IgA positivity; in 12 pts with CHD and 6 with UC with selective IgA deficiency anti-tTG or deamidated antigliadin IgG were normal; when performed duodenal histology never showed features consisting with CD. In two pts with CHD duodenal localization of the disease was diagnosed. In CD pts 12 showed persistent gastrointestinal complaints despite GFD without laboratory or imaging test suggesting IBD. Among these pts 7 reached final diagnosis of microscopic colitis, 4 refractory celiac disease, 1 intestinal lymphoma. Conclusions: In our IBD pts, prospective serologic and histological evaluation for coexisting undiagnosed CD did not allow any new diagnosis. On the other hand in a wide population of CD pts periodic follow-up did not provide any new diagnosis of coexisting IBD. Microscopic colitis are associated with CD and may be confused by unskilled pathologist with IBD. Screening for CD in patients with IBD should be reserved only in those pts with real clinical or laboratory suspicion of CD.